TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01640444
Drug: FOLFIRI + cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~* FOLFIRI:~  * Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~ * Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle).
Study: NCT01372410
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mcg once daily
Study: NCT02311998
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04496063
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
Study: NCT01560689
Drug: Budesonide/formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 800 µg/j twice a day, every day
Study: NCT01243697
Drug: desogestrel
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets of 75 µg, once daily during 112 days
Study: NCT02914691
Drug: Dapagliflozine 10 mg once daily tablet treatment
Normalized name: lisinopril
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04066790
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
Study: NCT04066790
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
Study: NCT04066790
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
Study: NCT01895257
Drug: systemic chemotherapy LV5FU2
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.~Cycle 1 onwards:~Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure.
Study: NCT01270789
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide administered as once daily sc injection
Study: NCT00657280
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: No one is blinded to the treatments.
Study: NCT03327155
Drug: Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
Study: NCT02860091
Drug: Ropivacaine infusion
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delivered via paravertebral nerve block catheter.
Study: NCT04066790
Drug: EC chemotherapy
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
Study: NCT02905994
Drug: Volasertib
Normalized name: Volasertib
DrugBank: Volasertib (DB12062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polo-Like Kinase Inhibitor
Study: NCT02905994
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard chemotherapy at dosage and schedule for 7+3 induction
Study: NCT02905994
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard chemotherapy at dosage and schedule for 7+3 induction
Study: NCT00216216
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2 IV q 3 weeks
Study: NCT01543724
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/kg/day for 12 weeks
Study: NCT02271997
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
Study: NCT02271997
Drug: Ferrous gluconate
Normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
Study: NCT00285402
Drug: AST-726 Low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00285402
Drug: AST-726 High dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00389233
Drug: Macrogol3350 Na sulphate Na bicarbonate NaCl KCl
Normalized name: polyethylene glycol 3350 / potassium chloride / sodium bicarbonate / sodium chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 pack will consist of 4L PEG + E - contains 4 sachets for the 4L of PEG + E/P/E. Each sachet will be dissolved in 1L of water. Each litre will be drunk within 1 hour.
Study: NCT01087931
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
Study: NCT02679170
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with crizotinib following routine clinical practice
Study: NCT01067326
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg Aliskiren once daily for a period of 4 months
Study: NCT02096289
Drug: Thioridazine
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03441984
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/3TC 30 mg, orally as direct-to-mouth.
Study: NCT03441984
Drug: Treatment D
Normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth.
Study: NCT03706339
Drug: intravenous tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section
Study: NCT03706339
Drug: Topical tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
Study: NCT04101708
Drug: Lansoprazole, Amoxicillin
Normalized name: lansoprazole, amoxicillin and levofloxacin
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose dual regimen
Study: NCT03441984
Drug: Treatment E
Normalized name: Benzoyl Peroxide 10% Topical application Cream [ACNE TREATMENT EXTRA STRENGTH]
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.
Study: NCT03441984
Drug: Treatment F
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
Study: NCT03489265
Drug: Eluxadoline 100 mg
Normalized name: eluxadoline 100 MG
DrugBank: Eluxadoline (DB09272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg capsule-shaped tablet by mouth taken twice per day
Study: NCT00711529
Drug: gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily). This dose has been shown to be more effective than 300mg daily. Larger doses have not been evaluated in this population, and may be associated with a more significant side-effect profile. The prescription for gabapentin will be provided at the patient's enrollment appointment. The patients will take gabapentin as prescribed daily for the study-enrollment period, which is 8 weeks.
Study: NCT00696761
Drug: Alfuzosin
Normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg, once daily, 12months
Study: NCT00000274
Drug: Flupenthixol
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01230788
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
Study: NCT00714597
Drug: Semuloparin sodium
Normalized name: Semuloparin
DrugBank: Semuloparin (DB06294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study: NCT00714597
Drug: Enoxaparin sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study: NCT03740997
Drug: Optison
Normalized name: Optison
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optison is administered intravenously
Study: NCT02626754
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
Study: NCT03735771
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine plus fentanyl 8 mcg/ml
Study: NCT04757532
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.
Study: NCT00372216
Drug: Clopidogrel (Iscover/Plavix)
Normalized name: clopidogrel Oral Tablet [Plavix]
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
Study: NCT04757532
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg of anastrozole (1 tablet) administered orally in a single dose.
Study: NCT04757532
Drug: Testosterone cyclopentylpropionate
Normalized name: Testosterone cyclopentylpropionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).
Study: NCT04757532
Drug: Danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg of danazol (1 capsule) administered orally in a single dose.
Study: NCT03118349
Drug: MVT-1075
Normalized name: magnesium oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
Study: NCT03118349
Drug: MVT-5873
Normalized name: magnesium oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
Study: NCT04269850
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.
Study: NCT04269850
Drug: Methylprednisone
Normalized name: Methylprednisone
DrugBank: Methylprednisone (DB12952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
Study: NCT00005074
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01597518
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
Study: NCT03452306
Drug: Metformine
Normalized name: Metformine
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition
Study: NCT03452306
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition
Study: NCT04140058
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron was administered 20 minutes prior to spinal anesthesia.
Study: NCT00373178
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00373178
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01670019
Drug: Asenapine 5-20 mg daily
Normalized name: asenapine 5 MG
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
Study: NCT00947713
Drug: low dose human chorionic gonadotropin
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
Study: NCT00947713
Drug: Clomiphen citrate plus HMG
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive Clomiphen Citrate plus HMG
Study: NCT02491268
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00891384
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
Study: NCT00796120
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin 1.5 milligram per square meter (mg/m\^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
Study: NCT00891384
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
Study: NCT02586454
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02586454
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01664104
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
Study: NCT00796120
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide 6 to 9 g/m\^2 will be given intravenously every 3 weeks until disease progression.
Study: NCT00340613
Drug: glargine insulin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02036931
Drug: Ceramic on Polyethylene articulation
Normalized name: polyethylenes
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)
Study: NCT01562951
Drug: ADALIMUMAB
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
Study: NCT00535119
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01677351
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mcg.kg-1, 20 minutes before cataract surgery
Study: NCT02279862
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03328533
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
Study: NCT03328533
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
Study: NCT00535119
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00535119
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00145925
Drug: Gliclazide MR-based glucose lowering
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01959048
Drug: fecal microbiota transplantation
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01220232
Drug: Abacavir/Lamivudine
Normalized name: ABACAVIR/LAMIVUDINE
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abacavir/Lamivudine 600/300 mg QD for 5 days
Study: NCT01220232
Drug: Abacavir/Lamivudine
Normalized name: ABACAVIR/LAMIVUDINE
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abacavir/Lamivudine 600/300 mg QD for 10 days
Study: NCT01220232
Drug: Lersivirine
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine 750 mg QD for 10 days
Study: NCT02232763
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of losartan or placebo with crossover to the other
Study: NCT00083005
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00083005
Drug: estramustine phosphate sodium
Normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00083005
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04371601
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir capsules
Study: NCT03618472
Drug: Metformin Hydrochloride 850 MG
Normalized name: metformin hydrochloride 850 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regular strength metformin (850 mg/tab)
Study: NCT01172509
Drug: R-baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral R-baclofen at 0x2, 3, 10, and 25 mg
Study: NCT03056911
Drug: Ozone
Normalized name: OZONE
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
Study: NCT01395316
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
Study: NCT01169935
Drug: Administration of Endorem
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose, intravenous